Skip to main content

Select Drug Profiles

Payers' Guide, FDA Approvals

Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death

Payers' Guide, FDA Approvals

Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals

Gary Branning, MBA

Payers' Guide, FDA Approvals

Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

Payers' Guide, FDA Approvals

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma

Lisa A. Raedler, PhD, RPh

Mitigating the Burden of Type 2 Diabetes: Challenges and Opportunities

Interview with the Innovators

Unclear Diagnoses in Patients with Metastatic Disease

Ralph V. Boccia, MD, FACP

Interview with the Innovators

The bioT3 platform

Ralph V. Boccia, MD, FACP

Page 138 of 244
Results 1371 - 1380 of 2438